KNSA insider trading — Kiniksa Pharmaceuticals International, plc
Over the last 90 days, insiders at Kiniksa Pharmaceuticals International, plc (KNSA) made 0 open-market purchases worth $0 and 1 open-market sale worth $299K, making them net sellers by $299K. The largest sale was by Cole G Bradley (Director), who sold 3,673 shares for $299K on Jul 29, 2026.
Updated Oct 16, 2026.
Recent KNSA insider transactions
Every Form 4 filed by Kiniksa Pharmaceuticals International, plc officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Ragosa Mark | CHIEF FINANCIAL OFFICER | M · Option exercise | Direct | 9,104 | — | — | Form 4 |
| Sep 1, 2026 | Ragosa Mark | CHIEF FINANCIAL OFFICER | F · Tax withholding | Direct | 4,404 | $79.28 | $349K | Form 4 |
| Sep 1, 2026 | Patel Sanj K | CHAIRMAN & CEO | M · Option exercise | Indirect | 62,636 | — | — | Form 4 |
| Sep 1, 2026 | Patel Sanj K | CHAIRMAN & CEO | F · Tax withholding | Indirect | 30,288 | $79.28 | $2.40M | Form 4 |
| Sep 1, 2026 | Paolini John F. | CHIEF MEDICAL OFFICER | M · Option exercise | Direct | 8,328 | — | — | Form 4 |
| Sep 1, 2026 | Paolini John F. | CHIEF MEDICAL OFFICER | F · Tax withholding | Direct | 4,029 | $79.28 | $319K | Form 4 |
| Sep 1, 2026 | Moat Ross | CHIEF OPERATING OFFICER | M · Option exercise | Direct | 8,285 | — | — | Form 4 |
| Sep 1, 2026 | Moat Ross | CHIEF OPERATING OFFICER | F · Tax withholding | Direct | 4,007 | $79.28 | $318K | Form 4 |
| Sep 3, 2026 | Megna Michael R | CHIEF ACCOUNTING OFFICER | S · Sale · 10b5-1 | Direct | 4,600 | $80.30 | $369K | Form 4 |
| Sep 1, 2026 | Megna Michael R | CHIEF ACCOUNTING OFFICER | M · Option exercise · 10b5-1 | Direct | 11,496 | — | — | Form 4 |
| Sep 1, 2026 | Megna Michael R | CHIEF ACCOUNTING OFFICER | F · Tax withholding · 10b5-1 | Direct | 5,531 | $79.28 | $438K | Form 4 |
| Jul 15, 2026 | Megna Michael R | CHIEF ACCOUNTING OFFICER | A · Grant/award · 10b5-1 | Direct | 279 | $33.50 | $9K | Form 4 |
| Aug 19, 2026 | Quart Barry D | Director | G · Gift | Direct | 2,600 | — | — | Form 4 |
| Aug 1, 2026 | Levy Richard S | Director | M · Option exercise | Direct | 403 | — | — | Form 4 |
| Jul 29, 2026 | Cole G Bradley | Director | S · Sale | Direct | 3,673 | $81.43 | $299K | Form 4 |
| Jul 29, 2026 | Cole G Bradley | Director | G · Gift | Direct | 4,500 | — | — | Form 4 |
KNSA insider trading FAQ
Are insiders buying KNSA stock?
Not on the open market. In the last 90 days, Kiniksa Pharmaceuticals International, plc insiders made no open-market purchases, and 1 open-market sale totaling $299K. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading KNSA?
Recent sellers: Cole G Bradley.
Where does KNSA insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.